tiprankstipranks
Advertisement
Advertisement
Buy Rating on MiNK Therapeutics Driven by Promising Phase 2 Survival Benefit and Immune Activation in PD-1–Refractory Gastric Cancer
PremiumRatingsBuy Rating on MiNK Therapeutics Driven by Promising Phase 2 Survival Benefit and Immune Activation in PD-1–Refractory Gastric Cancer
2M ago
MiNK Therapeutics management to meet virtually with B. Riley
Premium
The Fly
MiNK Therapeutics management to meet virtually with B. Riley
2M ago
MiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst
Premium
Ratings
MiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst
3M ago
3 Penny Stocks to Watch Now, 3/11/26
PremiumMarket News3 Penny Stocks to Watch Now, 3/11/26
3M ago
Morning News Wrap-Up 3/10/26: Tuesday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up 3/10/26: Tuesday’s Biggest Stock Market Stories!
3M ago
MiNK Therapeutics: Buy Rating Backed by Non-Dilutive PRAME iNKT Partnership and Expanded Oncology Upside
Premium
Ratings
MiNK Therapeutics: Buy Rating Backed by Non-Dilutive PRAME iNKT Partnership and Expanded Oncology Upside
3M ago
MiNK Therapeutics announces board resignation amid public appointment
PremiumCompany AnnouncementsMiNK Therapeutics announces board resignation amid public appointment
6M ago
MiNK Therapeutics announces publication of new preclinical data for MiNK-215
Premium
The Fly
MiNK Therapeutics announces publication of new preclinical data for MiNK-215
7M ago
MiNK Therapeutics Advances iNKT Platform in Q3 2025
Premium
Company Announcements
MiNK Therapeutics Advances iNKT Platform in Q3 2025
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100